ImmunityBio (IBRX) faces operational, financial, and competitive challenges, impacting its growth prospects despite Anktiva's ...

H.C. Wainwright analyst Andres Maldonado initiated coverage of ImmunityBio (IBRX) with a Buy rating and $8 price target ImmunityBio is a ...

We recently compiled a list of the Trade Tensions Weigh Heavily on 10 Stocks. In this article, we are going to take a look at ...

ImmunityBio shares advanced 17% to $3.34 after the company said the Food and Drug Administration awarded a regenerative medicine advanced therapy designation for Anktiva and CAR-NK for the reversal of ...

ImmunityBio (NASDAQ:IBRX) stock rose 10% Friday morning after the company said it has received Regenerative Medicine Advanced ...

After a momentous 2024, Culver City-based ImmunityBio Inc., the immunotherapy company founded and majority-owned by ...

Reports Q4 revenue $7.55M, consensus $9.51M. “The first quarter of 2025 has been an inflection point for the Company with multiple milestones ...

In addition, patients receiving ANKTIVA® + BCG achieved a 93% avoidance of cystectomy with a median follow up of 20.7 months. This immunotherapy of rescuing BCG with ANKTIVA (nogapendekin alfa ...

Cytokine fusion proteins, such as ANKTIVA, represent a novel class of biologics that improve immune responses by enhancing the therapeutic potential of cytokines and promoting lymphocyte ...

ImmunityBio’s revenue growth was driven by sales of its ANKTIVA therapy following FDA approval in April 2024. The company reported net product revenue of $7.2 million for Q4, representing a 21% ...

ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced certain operational results following approval of the permanent J-c ...